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Abstract
Background: Optimizing treatment through microarray-based molecular subtyping is a promising method to
address the problem of heterogeneity in breast cancer; however, current application is restricted to prediction of
distant recurrence risk. This study investigated whether breast cancer molecular subtyping according to its global
intrinsic biology could be used for treatment customization.
Methods: Gene expression profiling was conducted on fresh frozen breast cancer tissue collected from 327 patients
in conjunction with thoroughly documented clinical data. A method of molecular subtyping based on 783 probe-
sets was established and validated. Statistical analysis was performed to correlate molecular subtypes with survival
outcome and adjuvant chemotherapy regimens. Heterogeneity of molecular subtypes within groups sharing the
same distant recurrence risk predicted by genes of the Oncotype and MammaPrint predictors was studied.
Results: We identified six molecular subtypes of breast cancer demonstrating distinctive molecular and clinical
characteristics. These six subtypes showed similarities and significant differences from the Perou-Sørlie intrinsic
types. Subtype I breast cancer was in concordance with chemosensitive basal-like intrinsic type. Adjuvant
chemotherapy of lower intensity with CMF yielded survival outcome similar to those of CAF in this subtype.
Subtype IV breast cancer was positive for ER with a full-range expression of HER2, responding poorly to CMF;
however, this subtype showed excellent survival when treated with CAF. Reduced expression of a gene associated
with methotrexate sensitivity in subtype IV was the likely reason for poor response to methotrexate. All subtype V
breast cancer was positive for ER and had excellent long-term survival with hormonal therapy alone following
surgery and/or radiation therapy. Adjuvant chemotherapy did not provide any survival benefit in early stages of
subtype V patients. Subtype V was consistent with a unique subset of luminal A intrinsic type. When molecular
subtypes were correlated with recurrence risk predicted by genes of Oncotype and MammaPrint predictors, a
significant degree of heterogeneity within the same risk group was noted. This heterogeneity was distributed over
several subtypes, suggesting that patients in the same risk groups require different treatment approaches.
Conclusions: Our results indicate that the molecular subtypes established in this study can be utilized for
customization of breast cancer treatment.
Background
The advent of high-density DNA microarray technology
has enabled researchers to measure the expression of a
large number of genes in breast cancer and identify its
molecular subtypes [1-3]. In a seminal study by Perou et
al. [1], it was shown that breast cancer could be divided
into four intrinsic types according to their gene expres-
sion profiles. A later study revised this to six intrinsic
types [2]. Similar results were obtained when the same
set of classifier genes was applied to other breast cancer
datasets [4-6]. Other studies have also identified gene
expression signatures applicable to the prediction of risk
associated with regional recurrence, distant metastasis,
and survival [6-11].
Despite these advancements related to the intrinsic
types of breast cancer, the direct clinical application of
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yet to be realized. The clinical trials that have been
launched recently are based on prediction of distant
recurrence risk through gene expression [12,13]. These
approaches do not address the likely heterogeneity of
breast cancer within groups sharing the same predicted
risk. Thus, the approaches based on prediction of dis-
tant recurrence risk have not taken full advantage of
gene expression profiles to customize breast cancer
treatment according to molecular subtypes. Studies on
how microarray-based molecular subtypes could be cor-
related with outcomes of various specific treatment
regimes are sorely needed.
In addition, the existence of a specific subset of breast
cancer that can benefit most from anthracycline is still a
contentious issue. It remains uncertain whether patients
of this subset could be reliably identified according to
the over-expression of HER2 and TOP2A genes [14-17].
The possible identification of this subset of breast can-
cer patients through molecular subtypes classified
according to high dimensional gene expression remains
unexplored.
In seeking answers to these questions, we conducted a
retrospective gene expression profiling study on breast
cancer tissues collected from patients who had received
treatment and long-term clinical follow-up at our
institution.
Methods
Patients and Samples
Fresh frozen breast cancer tissue from every third
patient diagnosed and treated between 1991 and 2004 at
the Koo Foundation Sun-Yat-Sen Cancer Center
(KFSYSCC) were randomly selected for the study.
Patients with follow-up periods shorter than three years
were excluded, with the exception of those who died of
the disease within three years of the initial treatment. In
cases of ineligibility, the following sample was selected.
The selected tissue samples spanned the major transi-
tion periods of adjuvant chemotherapy from CMF
(cyclophosphamide, methotrexate and fluorouracil) to
CAF (cyclophosphamide, doxorubicin, fluorouracil) and
to taxane-based regimens. Four hundred forty seven
samples were obtained, but 135 samples were excluded
due to insufficient RNA (n = 1), poor RNA quality (n =
116), or unacceptable microarray quality (n = 18). A
total of 312 samples were eligible for the study (Cohort
1). Gene expression profiles of an additional 15 lobular
breast carcinoma samples, collected between 1999 and
2004 and previously studied, were also included (Cohort
2). All patients were treated by a multidisciplinary team
according to the guidelines consistent with the National
Comprehensive Cancer Network [18]. Following modi-
fied radical mastectomy or breast-conserving surgery
plus dissection of axillary nodes, patients received radio-
therapy, adjuvant chemotherapy, and/or hormonal ther-
apy, if indicated. Neoadjuvant chemotherapy was
administered to patients with locally advanced disease.
The study was approved by the institutional review
board (ID number 20020128A) and ethical approval was
obtained from the same board for samples without
obtainable informed consent.
mRNA Transcript Profiling
Total RNA was isolated using Trizol (Invitrogen, Carls-
bad, CA) and purified with the RNeasy Mini Kit (Qia-
gen, Valencia, CA). RNA quality was assessed using an
RNA 6000 Nano Kit and an Agilent 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany). The RNA
samples used for the study had an average RNA Integ-
rity Number of 7.85 ± 0.99 (mean ± SD). Hybridization
targets were prepared from total RNA according to the
Affymetrix protocol and hybridized to U133 plus 2.0
arrays. The expression intensity of each gene was scaled
to a trimmed-mean of 500, logarithmically transformed
to base 2 and normalized using quantile normalization.
The dataset and MIAME compliant information had
been deposited in the GEO database (GSE20685).
Breast Cancer Molecular Subtyping
Although the classifier genes of Perou-Sørlie intrinsic
types [2] could be applied to our datasets, such direct
application, crossing to a different microarray platform
for molecular subtyping could compromise the robust-
ness and accuracy of the classification. To establish a
reliable classification method specific to the Affymterix
microarray platform, we decided to develop and validate
a platform-specific methodology for the molecular sub-
typing of breast cancer. From the literature, we selected
23 pivotal genes known to play important roles in the
biology of breast cancer (Additional file 1, Table S1),
and subsequently conducted linear and quadratic corre-
lations with each of the 23 pivotal genes for all probe-
sets. The probe-sets showing significant degree of corre-
lation with any of the pivotal genes were further selected
according to their expression intensities, range of
expression, and density plot kurtosis. Finally, 783 probe-
sets were selected and used for molecular subtyping
(Additional file 1, Table S2). The procedures associated
with probe-set selection and two-step k means cluster-
ing for classification are detailed in the methodology in
the supplemental files (Additional File 2).
Validation of Breast Cancer Molecular Subtypes
The genes used for our molecular subtyping were
applied to three independent datasets for validation
[10,19,20]. Genes corresponding to our classification
probe-sets were identified in the published datasets. If
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independent datasets, the average intensity was calcu-
lated and applied. Centroid analysis was used to deter-
mine subtypes of breast cancer [5]. Hierarchical
clustering analysis was conducted to examine whether
the same subtypes identified in ours and three other
independent datasets shared the same differential
expression patterns for geneso fw o u n d - r e s p o n s e[ 9 ] ,
tumor stromal reaction [21], tumor vascular endothelial
normalization [22,23], and cell cycle proliferation (Addi-
tional file 1, Table S3).
Correlation Studies
In addition to examining the relationship between the
molecular subtypes of breast cancer identified in this
study and various clinical parameters, our classifier
genes were also applied to the other two published inde-
pendent breast cancer datasets for confirmation [10,24].
In addition, we used the reported genes of the Oncoty-
peDX [8] and MammaPrint [3] predictors to assess the
risk of distant recurrence for cases in all three datasets.
For prediction of recurrence risk by the genes of Onco-
typeDx predictor, we adopted the same statistical pre-
dictive model used by Paik et al. [8]. The molecular
subtypes were correlated with the predicted risk of
recurrence. The procedures of these studies are detailed
in the methodology section of Additional file 2.
Determination of ER, PR and HER2 Statuses by Microarray
To quantitatively determine the status of ER, PR,a n d
HER2,w eu s e dt h ei n t e n s i t yo fg e n ee x p r e s s i o nm e a -
sured by a microarray, because not all of the patients
had results for ER, PR, and HER2 by immunohistochem-
istry (IHC). The values of gene expression used to deter-
mine the positive or negative status of ER, PR,a n d
HER2 were based on density plots of 312 breast cancer
samples in Cohort 1 (Additional file 3, Figure S1). Bimo-
dal distribution was observed for all three genes, and the
cut-points were statistically determined, according to the
method described in the methodology section of Addi-
tional file 2. Studies into the correlation between the
results of IHC and gene expression for the status of ER
and HER2 showed significant positive correlations
(Additional file 3, Figure S2). This finding supports the
approach of using the intensity of gene expression to
determine the status of ER, PR, and HER2.
Statistical Methods
All statistical analysis was conducted using the SAS/
STAT software (ver. 9.1.3) (SAS Institute, Inc.) and the
R software package (v2.6) from Bioconductor (http://
www.bioconductor.org). Heat-maps were generated
using the R software (v2.9.1). All comparisons of survi-
val were performed using the log-rank test and all
Kaplan-Meier survival curves were plotted using S-Plus
software (ver. 6.0.2).
Results
Clinical Characteristics of Breast Cancer Patients
Table 1 summarizes the clinical characteristics of the
327 patients in our cohorts. Fifteen samples in cohort 2
were lobular carcinomas. Consequently, most breast
cancer samples in cohort 2 were positive for ER and PR
Table 1 Clinical characteristics of patients included in the
study
Cohort 1 (n = 312) Cohort 2 (n = 15)
No. % No. 15
Age at diagnosis
< 50 yr 197 63% 6 40%
≥ 50 yr 115 37% 9 60%
Treatment year
Before 1997 125 40% 0 0%
After 1997 187 60% 15 100%
TNM Stage
I 67 21% 2 13%
II 139 45% 8 53%
III 98 31% 5 33%
IV 8 3% 0 0%
Positive Lymph Nodes
0 132 42% 5 33%
1-3 83 27% 5 33%
4-9 58 19% 3 20%
≥ 10 35 11% 2 13%
Unavailable 4 1%
Nuclear Grade
1 25 8% 8 53%
2 83 27% 7 47%
3 202 65% 0 0%
Unavailable 2 1%
ER *
ER+ 190 61% 14 93%
ER- 122 39% 1 7%
HER2*
HER2+ 74 24% 1 7%
HER2- 238 76% 14 93%
PR*
PR+ 244 78% 14 93%
PR- 68 22% 1 7%
Treatment
Neoadjuvant Chemotherapy 31 10% 0 0%
Adjuvant Chemotherapy 220 71% 12 80%
Radiation Therapy 133 43% 8 53%
Hormonal Rx 210 67% 14 93%
No chemotherapy 50 16% 3 20%
*: ER, HER2 and PR status were determined according to microarray data.
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cases.
Clinical Characteristics of Molecular Subtypes of Breast
cancer
As shown in Figure 1, we classified breast cancer into
six different molecular subtypes. The 783 probe-sets
used for classification were grouped into 13 clusters
enriched with genes associated with cell cycle/prolifera-
tion, cell movement, metabolism, and reproductive sys-
tem development (Additional file 3, Figure S3). We then
conducted statistical analysis between the molecular
subtypes and various clinical parameters (Table 2). The
results summarized in Table 2 show that by the T stage,
smaller tumors dominated in subtypes V and VI, while
larger tumors dominated in subtypes II, III and IV (p =
2×1 0
-5) .T h em a j o r i t yo fp a t i e n t si ns u b t y p e sI V ,V
and VI were positive for ER and PR (p = 6.3 × 10
-51 and
2.3 × 10
-18, respectively). Interestingly, all subtype V
breast cancers were positive for ER and PR and negative
for HER2. In contrast, all subtype I breast cancers were
negative for ER. Nearly all subtype II breast cancers
were negative for ER (97%), and the majority had over-
expression of HER2 (76.5%) (p = 9.1 × 10
-20). Subtype
III comprised breast cancers that had weaker ER and
variable PR and HER2 expression (data not shown).
Subtype IV had full range expression of HER2. Subtype
II had the greatest propensity to develop distant metas-
tases (47%) followed by subtypes IV (36%) and VI (24%),
while subtype V was least likely to metastasize (5%) (p =
2.5 × 10
-5). Figure 2 shows the survival curves of all six
molecular subtypes. The statistical results of comparing
survival outcomes between any two molecular subtypes
are summarized in Table 3.
Molecular Characteristics and Validation of Breast Cancer
Subtypes
To demonstrate the biologically distinctive nature of six
different subtypes of breast cancer, we studied the dif-
ferential expressions of genes associated with cell cycle/
proliferation, wound-response [9], stromal reaction [21]
and vascular endothelial normalization [22,23] using
one-way clustering analysis. Genes used in this study
were not used for molecular subtyping. As shown in
Figure 3, all six molecular subtypes demonstrated dis-
tinct gene expression characteristics. The dendrograms
of the probe-sets and the probe-set IDs are summarized
in Figure S4 of Additional file 3. For validation, we used
our classifier genes with centroid analysis to determine
molecular subtypes of breast cancer samples in three
independent datasets [10,19,20]. We then compared dif-
ferential gene expression patterns associated with cell
cycle/proliferation, wound-response, stromal reaction
and vascular endothelial normalization for the same
molecular subtypes between our dataset and the other
three independent datasets. The same molecular sub-
types in all four datasets were shown to share the same
differential gene expression patterns (Figure 3). For
further validation, we employed a different approach.
We selected five genes (CAV1, DHFR, TYMS, VIM,
ZEB1) known to be associated with drug sensitivity and
the epithelial-mesenchymal transition of breast cancer
[25-29]. The intensity of expression of these genes was
plotted according to molecular subtypes. Again, each
m o l e c u l a rs u b t y p es h a r e dt h es a m eu n i q u em o l e c u l a r
Figure 1 Heat map of different molecular subtypes of breast
cancer. The dendrogram of the 783 classification probe-sets is
shown on the left and 327 breast cancer samples clustered into six
molecular subtypes are shown at the top. The approach used to
generate these six molecular subtypes is detailed in the Additional
file 2.
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Subtype I Subtype II Subtype III Subtype IV Subtype V Subtype VI Fisher’s exact
test
N = 37 N = 34 N = 41 N = 81 N = 41 N = 93 p value
Age at diagnosis
< 50 yr 27 73.0% 16 47.1% 30 73.2% 54 66.7% 22 53.7% 54 58.1%
>= 50 yr 10 27.0% 18 52.9% 11 26.8% 27 33.3% 19 46.3% 39 41.9% 0.08
T stage
1 8 21.6% 4 11.8% 10 24.4% 16 19.8% 22 53.7% 41 44.1%
2 28 75.7% 23 67.6% 20 48.8% 56 69.1% 17 41.5% 44 47.3%
3 1 2.7% 5 14.7% 7 17.1% 5 6.2% 1 2.4% 7 7.5%
4 0 0.0% 2 5.9% 4 9.8% 4 4.9% 1 2.4% 1 1.1% 2.00E-05
N stage
0 20 54.1% 7 20.6% 16 39.0% 31 38.3% 20 48.8% 43 46.2%
1 10 27.0% 10 29.4% 8 19.5% 25 30.9% 12 29.3% 22 23.7%
2 4 10.8% 11 32.4% 11 26.8% 14 17.3% 7 17.1% 16 17.2%
3 3 8.1% 6 17.6% 6 14.6% 11 13.6% 2 4.9% 12 12.9% 0.26
Pos. Lym.
Nodes
0 20 54.1% 6 17.6% 16 39.0% 31 38.3% 20 48.8% 43 46.2%
1-3 10 27.0% 10 29.4% 8 19.5% 26 32.1% 12 29.3% 22 23.7%
4-9 4 10.8% 11 32.4% 10 24.4% 13 16.0% 7 17.1% 16 17.2%
> = 10 3 8.1% 5 14.7% 6 14.6% 9 11.1% 2 4.9% 12 12.9% 0.30
M stage
0 36 97.3% 33 97.1% 40 97.6% 78 96.3% 41 100.0% 91 97.8%
1 1 2.7% 1 2.9% 1 2.4% 3 3.7% 0 0.0% 2 2.2% 0.94
TNM Stage
I 6 16.2% 2 5.9% 10 24.4% 9 11.1% 12 29.3% 28 30.1%
II 23 62.2% 13 38.2% 11 26.8% 46 56.8% 18 43.9% 36 38.7%
II 6 16.2% 18 52.9% 19 46.3% 23 28.4% 10 24.4% 27 29.0%
IV 1 2.7% 1 2.9% 1 2.4% 3 3.7% 0 0.0% 2 2.2% 7.60E-04
Nuclear
Grade
1 1 2.7% 0 0.0% 2 4.9% 2 2.5% 9 22.0% 17 18.3%
2 3 8.1% 1 2.9% 4 9.8% 11 13.6% 18 43.9% 38 40.9%
3 30 81.1% 28 82.4% 33 80.5% 62 76.5% 10 24.4% 33 35.5% 0
ER*
positive 0 (2) 0.0% (5%) 1 (6) 2.9%
(20.6%)
10
(13)
24.4%
(36%)
70
(66)
86.4%
(90.4%)
41
(36)
100.0%
(97.2%)
82
(75)
88.2%
(91.5%)
negative 37
(34))
100.0%
(95%)
33
(23)
97.1%
(79.4%)
31
(23)
75.6%
(64%)
11
(7)
13.6%
(9.6%)
0 (1) 0.0% (2.8%) 11
(7)
11.8%
(8.5%)
6.31E-51
HER2*
positive 4 (2) 10.8%
(11.8%)
26
(9)
76.5%
(81.8%)
18
(16)
43.9%
(66.7%)
22
(11)
27.2%
(33.3%)
0 (2) 0.0%
(13.3%)
5 (7) 5.4%
(15.9%)
negative 33
(17)
89.2%
(88.2%)
8 (2) 23.5%
(18.2%)
23
(8)
56.1%
(33.3%)
59
(22)
72.8%
(66.7%)
41
(13)
100.0%
(86.7%)
88
(37)
94.6%
(84.1%)
9.09E-20
PR*
positive 19 (9) 51.4%
(25%)
14
(11)
41.2%
(37.9%)
23
(16)
56.1%
(44.4%)
73
(64)
90.1%
(87.7%)
41
(34)
100.0%
(91.9%)
88
(70)
94.6%
(85.4%)
negative 18
(27)
48.6%
(75%)
20
(18)
58.8%
(62.1%)
18
(20)
43.9%
(55.6%)
8 (9) 9.9%
(12.3%)
0 (3) 0.0% (8.1%) 5
(12)
5.4%
(14.6%)
2.26E-18
Local Relapse
No 31 83.8% 27 79.4% 39 95.1% 68 84.0% 34 82.9% 86 92.5%
Yes 6 16.2% 4 11.8% 1 2.4% 8 9.9% 3 7.3% 6 6.5% 0.29
Regional
Relapse
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Figure S5).
Correlation of Molecular Subtypes with Perou-Sørlie
Intrinsic types
To study how the molecular subtypes of breast cancer
used in this study are correlated with the Perou-Sørlie
intrinsic types [1,2], we applied the classifier genes used
by Perou-Sørlie [2] to our samples. As shown in Figure
4, there were both similarities and considerable
differences between the two classification methods. A
high degree of concordance was noted between our sub-
type I and the basal-like intrinsic type. When we applied
our classification genes to the NKI dataset [24], wherein
we also noticed an 89% concordance between our sub-
type I and the basal-like intrinsic type. The high degree
of concordance was likely the result of the very distinc-
tive features of this subtype of breast cancer.
Nevertheless, most of the Perou-Sørlie luminal A
intrinsic type was divided into subtypes V and VI
according to our classification genes (Figure 4). When
we compared metastasis free survival between subtypes
V and VI of the luminal A intrinsic type breast cancer
patients in our cohorts, significantly better metastasis-
free survival was observed for the subtype V patients
comparing to the subtype VI (p = 0.025) (Additional file
3, Figure S6). There were no significant differences in
disease severity (T stage p = 0.33, N stage p = 0.50, M
stage p = 1, positive axillary lymph node number p =
0.50, and nuclear grade p = 1), however. The differentia-
tion of subtypes V and VI breast cancer within the lumi-
nal A intrinsic type is therefore clinically significant. The
distinction was further supported by the differential
gene expression patterns for wound response and vascu-
lar endothelial normalization between these two sub-
types of breast cancer (Figure 3).
The cases of HER2 over-expressing intrinsic type, they
were divided into molecular subtypes II and III (Figure
4). We noted that cases of molecular subtype III cases
classified as HER2 over-expressing intrinsic type
expressed ER at a level higher than the subtype II and
HER2 over-expressing intrinsic type (the average inten-
sity of gene expression in logarithm to base 2 were 9.9
± 0.96 vs. 8.6 ± 1.0, p < 0.0001). It appears that our
molecular subtyping have discerned different subsets
within the HER2 over-expressing intrinsic type. In this
study, we did not find normal-breast like intrinsic type
breast cancer in our cohorts.
Differential Treatment Responses of Breast Cancer
Molecular Subtypes
The breast cancer samples included in this study cov-
ered the period of transition of adjuvant chemotherapy
regimen from CMF to CAF and to taxane-based
Table 2 Statistical comparison of clinical features among molecular subtypes (Continued)
No 32 86.5% 26 76.5% 37 90.2% 67 82.7% 36 87.8% 84 90.3%
Yes 2 5.4% 5 14.7% 3 7.3% 6 7.4% 1 2.4% 8 8.6% 0.54
Distant
metastasis
No 31 83.8% 15 44.1% 33 80.5% 50 61.7% 39 95.1% 70 75.3%
Yes 6 16.2% 16 47.1% 8 19.5% 29 35.8% 2 4.9% 22 23.7% 2.51E-05
*: Numbers in parentheses are results determined by immunohistochemistry. For HER2, 3+ was regarded as positive. P values for ER, HER2 and PR by IHC among
all six molecular subtypes were 3 × 10
-36,2×1 0
-4 and 1.4 × 10
-14, respectively.
Figure 2 Metastasis-free and overall survival curves of six
different molecular subtypes of breast cancer. Numbers in the
parentheses are events. The p values were determined by log-rank
test. The p values of log-rank test between any two of the six
molecular subtypes are summarized in Table 3.
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nity to examine how breast cancer subtypes might have
responded differentially to CMF and CAF regimens of
adjuvant chemotherapy. The results of this study show
that the change from methotrexate to doxorubicin had a
major impact on the survival of patients with subtype
IV breast cancer (Figure 5). None of the pertinent clini-
cal factors between these two groups of patients showed
a significant difference except for the N stage. The N
stage was higher in the CAF group (Table 4). In spite of
the higher N stage, significantly better metastasis-free
and overall survival was observed for subtype IV
patients treated with CAF than with CMF (Figure 5).
For other molecular subtypes, we did not find significant
differences in survival between groups receiving treat-
ment with CAF or CMF (Additional file 1, Table S5).
The small sample size did not allow us to draw firm
conclusions regarding survival in molecular subtypes
other than subtype IV.
A number of patients in our cohorts opted not to
receive adjuvant chemotherapy even though it was
indicated. This allowed us to study how the omission
of adjuvant chemotherapy might have influenced
patient survival among various subtypes of breast can-
cer. In a comparison of disease severity between those
with and without adjuvant chemotherapy in each sub-
type, only patients with subtype V showed no signifi-
cant difference (Table 5), thereby offering an
interpretable comparison. As shown in Figure 6, the
metastasis-free and overall survivals of subtype V were
essentially the same between those who received adju-
vant chemotherapy and those who did not. This sug-
g e s t st h a ta d j u v a n tc h e m o t h e r a p yd i dn o tp r o v i d e
survival benefits to subtype V patients in the early
stages; however, this would require further confirma-
tion due to small sample size.
To seek further support of our finding, we studied
patients from the NKI dataset with subtype V breast can-
cer of N1 stage [24]. This dataset includes treatment and
survival outcome information, and many patients in this
dataset did not receive adjuvant chemotherapy. The distri-
bution of tumor size and fraction of patients treated with
hormone therapy were not significantly different between
those who received adjuvant chemotherapy and those who
did not. The p values determined by Fisher’s exact test
were 0.32 and 1.0, respectively. Stage N0 patients were
excluded because an overwhelming number were not trea-
ted with adjuvant chemotherapy. The results showed that
there was no difference in survival between stage N1 sub-
type V patients treated with adjuvant chemotherapy and
those who were not (Figure 6).
As mentioned earlier, subtype I breast cancer was
essentially the same as the basal-like intrinsic type (Fig-
ure 4), and this subtype of breast cancer is known to be
chemosensitive [30]. The five and ten year survival rates
of patients with basal-like breast cancer who did not
receive adjuvant chemotherapy were 64% and 44%,
r e s p e c t i v e l y[ 2 4 ] .T h i si sc o n s i s t e n tw i t ht h ef a c tt h a t
basal-like breast cancer has aggressive clinical course
and poor survival without adjuvant chemotherapy [31].
When we studied the survival of patients with subtype I
breast cancer following CMF or CAF adjuvant che-
motherapy, it was noticed that both groups had good
long-term survival outcome based on the results from a
limited number of patients (Figure 7). This suggests that
subtype I breast cancer responds well to CMF adjuvant
chemotherapy, and this finding is supported by a recent
study of two large randomized clinical trials in which
patients with node negative basal-like breast cancer
were sensitive and responsive to CMF adjuvant che-
motherapy and had good long-term survival following
treatment [32]. Adjuvant chemotherapy is therefore
Table 3 P values of log-rank test for metastasis-free and overall survival between any two molecular subtypes
p values of log rank test between molecular subtypes for metastasis-free survival
II III IV V VI
I 0.0072 0.7554 0.0467 0.0910 0.4455
II 0.0081 0.1431 6.4E-06 0.0039
III 0.0727 0.04 0.6582
IV 0.0003 0.0704
V 0.0094
p values of log rank test between molecular subtypes for overall survival
II III IV V VI
I 0.0062 0.9855 0.1702 0.0947 0.8725
II 0.0066 0.0521 1.6E-05 0.0001
III 0.1534 0.0484 0.6917
IV 0.0009 0.0335
V 0.0778
P values < 0.05 are shown in bold type.
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Page 7 of 15Figure 3 Validation of molecular subtypes of breast cancer established in this study. One-way hierarchical clustering analysis was
performed on 327 samples in our dataset using genes associated with cell cycle/proliferation, wound-response [9], stromal reaction [21], and
tumor vascular endothelial normalization [22,23]. Breast cancer samples were arranged according to their subtype as shown at the top of each
panel. Dendrograms of signature genes are shown on the left. The identities of genes in all four dendrograms are listed in the Additional file 3,
Figure S4. None of the genes used in this study were part of the 783 probe-sets used for molecular subtyping. The same gene clusters
generated from our dataset were used to draw heat maps for the other three independent datasets. The heat maps from top to bottom for
each signature were KFSYSCC, EMC [10], Uppsala [19], and TRANSBIG [20]. Each molecular subtype shared the same distinctive gene expression
pattern among all four datasets. Subtypes I, II and IV showed increased expressions of cell cycle/proliferation genes. Subtypes I and II showed
higher expression of stromal genes known to associate with poorer survival [21]. Subtypes III and VI had elevated expression of genes associated
with vascular endothelial normalization. The concordance of differential gene expression for the six molecular subtypes between the KFSYSCC
dataset and each of the other three independent datasets [10,19,20] was analyzed by Pearson correlation. The p value for each correlation
coefficient was determined by comparing with null distribution based on 10,000 permutations of each independent dataset at subtype level. The
Pearson correlation coefficient between the KFSYSCC dataset and that of EMC, Uppsala or TRANSBIG was 0.94, 0.92 or 0.87 for cell cycle/
proliferation, 0.85, 0.84 or 0.78 for wound response, 0.94, 0.91 or 0.87 for stromal reaction, and 0.86, 0.86 or 0.83 for tumor vascular endothelial
normalization. All p values were < 0.0001.
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Page 8 of 15critical for the long-term survival of patients with early
stage subtype I breast cancer. The use of less toxic CMF
could be as effective as CAF and deserves further study.
Correlation of Molecular Subtypes with Risk of
Recurrence Predicted by Oncotype™DX and
MammaPrint
®
Oncotype and MammaPrint predictors are used to pre-
dict the risk of distant recurrence in breast cancer
patients for the optimization of treatment [12,13,33]. To
learn how the groups with varying levels of the pre-
dicted risk are correlated with molecular subtypes of
breast cancer, we conducted a study on patients in our
dataset and the other two independent datasets [10,24].
We determined molecular subtypes and the scores of
relative risk of distant recurrence. The results, summar-
ized in Figure 8, reveal that patients with a high risk of
distant recurrence according to the genes of Oncotype
predictor included both subtypes I (basal-like) and II
(HER2 over-expressing). Low risk cases were mostly
subtypes V and VI, while most intermediate risk cases
were subtypes III and IV. The high-risk cases predicted
by the genes of MammaPrint included most of subtype I
and many of subtypes II, III and IV, with low risk cases
limited to subtypes V and VI (Figure 8). The results
were consistent across all three datasets; thus, breast
cancer within the same predicted risk group is heteroge-
neous according to molecular subtype. Patients within
the same risk group may require different therapeutic
approaches for better survival outcome.
Discussion
This paper reports the results of a gene expression pro-
filing study in which breast cancer samples were col-
lected over a fourteen year period (1991-2004). The
study was prompted by the fact that the current clinical
application of microarray-based prediction for the custo-
mization of breast cancer treatment is restricted to pre-
dicting the risk of distant recurrence (e.g. MammaPrint).
The clinical application of molecular subtypes based on
high dimensional gene expression profiles reflecting the
intrinsic biology of breast cancer remains unrealized.
One reason for this lack of progress has to do with the
absence of preliminary reports on how microarray-based
molecular subtypes could be correlated with clinical out-
comes resulting from varioust r e a t m e n t so fb r e a s tc a n -
cer. The long duration covered by our study enabled us
to investigate how a change in adjuvant chemotherapy
regimens might have influenced the survival outcome of
patients with various molecular subtypes of breast
cancer.
It is known that different designs of microarray plat-
forms and methods of preparing mRNA targets could
lead to less-than-perfect direct cross-platform applica-
tion of classifier genes [34-36]. To establish a reliable
and robust methodology for molecular subtyping for
this study and future clinical application, we developed
and validated a platform-specific method. Our classifica-
tion method is based on the assumptions that genes
with expression levels quantitatively correlated with the
expression of pivotal genes play important roles in
Figure 4 Correlation of the molecular subtypes with the Perou-
Sørlie intrinsic types. The top row shows the color-coded
molecular subtypes of 327 samples in our dataset, and the lower
panel shows how the same cases on top were classified into the
basal (green), HER2-overexpressing (red), luminal A (blue) and
luminal B (brown) intrinsic types using the classification genes of
Sørlie, et al. [2]. The results show both similarities and differences
between the results of these two classification methods.
Figure 5 Comparison of survival outcome between patients
with molecular subtype IV breast cancer treated with CMF and
CAF. Detailed comparisons of pertinent clinical parameters between
these two treatment groups are summarized in Table 4. The
numbers in parentheses represent the number of events. P values
were determined by log-rank test. The upper panel is metastasis-
free survival curves and the lower panel is overall survival curves.
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Page 9 of 15determining the biology and clinical behavior of breast
cancer, and that genes with a low kurtosis score and
more than one peak distribution could be robust for
classification. Six different molecular subtypes showing
distinctive molecular characteristics and clinical beha-
vior were identified.
For validation, we applied our classifier genes to three
independent datasets [10,19,20] and examined whether
each molecular subtype in the different datasets shared
the same unique gene expression patterns associated
with cell cycle proliferation, wound response, stromal
reaction and vascular endothelial normalization of
tumors, in each of the datasets. We found that the same
subtype shared the same unique gene expression pat-
terns across all datasets (Figure 3). The selection of this
validation approach enabled us to avoid heterogeneity in
clinical outcomes associated with various approaches of
treatment and patient selection criteria used in different
gene expression profiling datasets.
Table 4 Statistical comparison of pertinent clinical
parameters between subtype IV patients treated with
CAF and CMF adjuvant chemotherapy
Molecular Subtype IV breast Cancer
CAF CMF p value*
Patients (n = 22) Patients (n = 17)
Age at diagnosis 0.464
< 50 yr 15 68.2% 14 82.4%
>= 50 yr 7 31.8% 3 17.6%
TNM Path T 0.612
1 3 13.6% 2 11.8%
2 19 86.4% 13 76.5%
3 0 0.0% 1 5.9%
4 0 0.0% 1 5.9%
TNM Path N 0.047
0 9 40.9% 11 64.7%
1 12 54.5% 3 17.6%
2 1 4.5% 2 11.8%
3 0 0.0% 1 5.9%
TNM Path M 0.436
0 22 100.0% 16 94.1%
1 0 0.0% 1 5.9%
Positive Lymph Nodes 0.067
0 9 40.9% 11 64.7%
1-3 12 54.5% 3 17.6%
4-9 1 4.5% 2 11.8%
TNM Stage 0.109
I 0 0.0% 2 11.8%
II 21 95.5% 12 70.6%
III 1 4.5% 2 11.8%
IV 0 0.0% 1 5.9%
Nuclear Grade 0.495
1 1 4.5% 0 0.0%
2 2 9.1% 0 0.0%
3 19 86.4% 17 100.0%
Post-op Radiation Rx 1.000
No 14 63.6% 11 64.7%
Yes 8 36.4% 6 35.3%
*: p values were determined by Fisher’s exact test.
There was no difference in follow-up duration between two groups (median
9.0 vs. 7.5 years, p = 0.90 by Wilcoxon rank sum test).
Table 5 Statistical comparison of pertinent clinical
parameters between subtype V patients treated with and
without adjuvant chemotherapy
Molecular Subtype V Breast Cancer
Adjuvant Rx No-Adjuvant
Rx
p values*
Patient
(n = 28)
Patient
(n = 12)
Age at diagnosis
< 50 yr 16 57.1% 5 41.7% 0.49
>= 50 yr 12 42.9% 7 58.3%
TNM Path T
1 14 50.0% 8 66.7% 0.14
2 14 50.0% 3 25.0%
3 0 0.0% 0 0.0%
4 0 0.0% 1 8.3%
TNM Path N
0 13 46.4% 7 58.3% 0.86
1 8 28.6% 4 33.3%
2 5 17.9% 1 8.3%
3 2 7.1% 0 0.0%
TNM Path M
0 28 100.0% 12 100.0%
Positive Lymph Nodes
0 13 46.4% 7 58.3% 0.86
1-3 8 28.6% 4 33.3%
4-9 5 17.9% 1 8.3%
> = 10 2 7.1% 0 0.0%
TNM Stage
I 7 25.0% 6 50.0% 0.34
II 14 50.0% 4 33.3%
III 7 25.0% 2 16.7%
Nuclear Grade
1 4 14.3% 5 41.7% 0.17
2 13 46.4% 4 33.3%
3 8 28.6% 2 16.7%
Hormonal Therapy
No 3 10.7% 2 16.7% 0.63
Yes 25 89.3% 10 83.3%
Post-op Radiation Rx
No 20 71.4% 9 75.0% 1.00
Yes 8 28.6% 3 25.0%
*: p values were determined by Fisher’s exact test
There was no difference in follow-up duration between two groups (median
10.4 vs. 9.2 years, p = 0.17 by Wilcoxon rank sum test)
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Page 10 of 15Our method of breast cancer molecular subtyping was
also validated by the consistent correlations between the
molecular subtypes generated by our classifier genes and
the risk of distant recurrence predicted by the genes
used in the Oncotype and MammaPrint predictors
among three different datasets (Figure 8). We noted that
a disproportionally low number of cases of subtype VI
breast cancer cases in the NKI dataset. This was likely
due to the cross-platform application of our classifier
genes to the NKI dataset. We were unable to reliably
differentiate subtypes V and VI breast cancer in the NKI
dataset. However, this failure did not influence the con-
clusions drawn from this study, because both subtypes
V and VI were predicted as low risk for distant recur-
rence in all three datasets (Figure 8). The results of this
study reveal that the same risk group predicted by the
genes of Oncotype or MammaPrint predictor comprises
different molecular subtypes of breast cancer (Figure 8).
The present study suggests that different molecular
subtypes of breast cancer within a group sharing the
same predicted risk of distant recurrence could benefit
from different treatments. For instance, the groups pre-
dicted as high-risk by the genes of Oncotype predictor
include subtypes I, II, III and IV. Nevertheless, subtype I
breast cancer was chemosensitive and could respond
equally well to CMF and CAF in the early stages (Figure
7). Despite of the small sample size, this conclusion is
supported by a recent study of two large-scale clinical
trials showing that triple negative basal-like breast can-
cer responds well to the treatment of CMF adjuvant
chemotherapy [32]. In contrast, subtype IV breast cancer
appeared resistant to methotrexate and sensitive to a
Figure 6 Comparison of survival outcome between subtype V patients with and without adjuvant chemotherapy. Comparisons of
survival were conducted for patients in our dataset (upper panels) and the NKI dataset [24] (lower panels). The comparison of pertinent clinical
parameters showed no differences between the two treatment groups from our KFSYSCC dataset (Table 5). Patients with subtype V breast
cancer in the NKI database were identified using the classifier genes established in this study and centroid analysis. All NKI patients with N1
stage disease were selected for comparison. Tumor size distribution and the fraction of patients treated with hormonal therapy were not
significantly different between the two treatment groups, with respective p values of 1.0 and 0.32 using Fisher’s exact test. The NKI stage N0
patients were not included in this study because an overwhelming number did not receive adjuvant chemotherapy. Their inclusion would have
caused an uneven distribution of disease severity. The results show that adjuvant chemotherapy did not provide survival benefit for patients
with early stage subtype V breast cancer in either dataset.
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Page 11 of 15chemotherapy regimen containing anthracycline (Figure
5). We also noticed good survival outcome in subtype
IV breast cancer patients who had an over-expression of
HER2 and were treated with CAF without trastuzumab.
It appears that subtype IV breast cancer patients with
over-expression of HER2 could be adequately treated
with chemotherapy regimen containing anthracycline
without costly trastuzumab. In contrast, subtype II
breast cancer patients with over-expression of HER2
had the worst survival despite adjuvant chemotherapy
(Figure 2). Patients of this subtype may benefit most
from trastuzumab therapy or other tyrosine kinase
receptor inhibitors.
Patients in the group predicted as having low risk for
distant recurrence were mostly classified as subtype V or
VI (Figure 8). The results of this study show that subtype
V is a unique subset of the Perou-Sørlie luminal A intrin-
sic type (Table 2, Figure 4 and Figure 6). Early stage sub-
type V patients had excellent survival outcome even
w i t h o u ta d j u v a n tc h e m o t h e r apy (Figure 6). This finding
was confirmed by comparing the survival of subtype V
patients from the NKI dataset who had received adjuvant
Figure 8 Correlation between molecular subtypes and distant recurrence risks predicted by the Oncotype and MammaPrint predictor.
The three different datasets used in this study included ours (KFSYSCC), the EMC [10] and the NKI [24]. The number of cases in each subtype for
the KFSYSCC, EMC, and NKI datasets were 37, 49, and 10 for subtype I; 34, 24, and 18 for subtype II; 41, 24, and 4 for subtype III; 81, 80, and 52
for subtype IV; 41, 39 and 172 for subtype V; and 93, 70 and 9 for subtype VI, respectively. The method used to score the risk of distant
recurrence is detailed in Additional File 2. For prediction of recurrence risk by genes of the Oncotype predictor, a higher score represents a
higher risk of recurrence. The negative correlation scores predicted by the MammaPrint predictor shown on the y axis represent higher risk of
distant recurrence. A score of <0 can be defined as high risk for recurrence and a score of = or >0 as low risk.
Figure 7 Comparison of overall survival between subtype I
patients treated with CAF and CMF adjuvant chemotherapy.
Clinical variables including age at diagnosis, TNM stages, positive
lymph node number, nuclear grade, hormonal therapy and post-op
radiation were compared between these two treatment groups.
There were no significant differences (Additional file 1, Table S6).
The results of this small sample size study are supported by a
recent report on two large-scale clinical trials [32].
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Page 12 of 15chemotherapy and those who had not (Figure 6). The
absence of benefit from adjuvant chemotherapy for sub-
type V patients was also supported by a recently study in
which most stage II-III breast cancer patients predicted
by MammaPrint as having a low risk of recurrence did
not respond to neoadjuvant chemotherapy [37].
Patients with subtype VI had a higher risk of develop-
ing distant metastasis than those with subtype V breast
cancer (Figure 2 and Table 3). Our study also showed
that subtypes V and VI have very different molecular
characteristics. For instance, like subtype III, subtype VI
has a strong vascular endothelial normalization signa-
ture, but this is not the case for subtype V (Figure 3).
Subtype VI has a significantly higher expression of
genes characteristic of epithelial-mesenchymal transition
(e.g. TWIST2, SNAI2, ZEB2, VIM) than subtype V
(Additional file 3, Figure S7). For this reason, adjuvant
chemotherapy may not be safely omitted from the treat-
ment of patients with subtype VI. Differentiation
between these two molecular subtypes can be clinically
important. For the reasons discussed above, treatment
of breast cancer patients in groups with the same risk of
recurrence requires further customization, according to
the respective molecular subtype of the disease.
Identification of subtype IV breast cancer in the pre-
sent study may have provided answer to an ongoing
debate regarding the presence and identification of a
subset of breast cancer showing excellent response to
anthracycline [14-16]. According to the results of our
study, only subtype IV breast cancer showed a signifi-
cantly different response to treatment with CAF or
CMF adjuvant chemotherapy (Figure 5). TOP2A is
known as a target for anthracyclines. Breast cancer with
increased TOP2A expression has been reported to be
more sensitive to anthracycline [15,38]. Both subtypes I
and IV breast cancer in our study indeed had the high-
est TOP2A expression among the six molecular subtypes
(Figure 9). With regard to drug sensitivity to methotrex-
ate, it is known that an increase in the expression of
DHFR and reduced expression of genes involved in
methotrexate transport (SLC19A1 and FOLR1)a n d
retention (FPGS) can contribute to resistance to metho-
trexate [39]. Statistical comparisons of the expression of
the genes between subtype I and IV showed significant
differences in the expression of folate receptor alpha
(FOLR1) (Figure 9) with no differences for SLC19A1,
FPGS or DHFR. The reduced expression of FOLR1
might have contributed to the poor response of subtype
IV breast cancer to the methotrexate-containing CMF
regimen. Therefore, treating subtype IV breast cancer
with anthracycline-containing regimen is critical.
Conclusions
Results of this study indicate that breast cancer can be
classified into six different molecular subtypes using
Affymetrix U133 plus 2.0 GeneChip™. These six
Figure 9 Average expression intensity of TOP2A and FLOR1 genes in different molecular subtypes of breast cancer. All patients (n =
327) in our dataset were included in the study. The average expression of each gene is shown as mean ± SEM. Student t test was conducted
between subtype IV and other subtypes following logarithmic transformation of expression intensities to base of 2. TOP2A expression of subtype
IV was significantly higher than subtype II, III, V and VI with p values of < 0.0001 (*). There was no significant difference between subtype IV and
I. For expression of FLOR1, subtype IV was significantly lower than subtypes I with p < 0.0001(*). The number of samples in each subtype is
available in Table 2.
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Page 13 of 15subtypes show both significant similarities and differ-
ences with the Perou-Sørlie intrinsic types, and have dis-
tinctive molecular and clinical characteristics. The
correlation between molecular subtypes and responses
to treatments demonstrates that microarray-based mole-
cular subtyping in conjunction with pertinent clinical
data can be used for the customization and optimization
of breast cancer treatment. Carefully designed prospec-
tive clinical trials will be needed to confirm such clinical
utility.
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Additional file 1: Supplemental Tables S1-S6. This set of additional
files includes the following supplemental tables. Table S1 Twenty
three pivotal genes used to identify probe-sets showing linear or
quadratical correlation. Table S2 List of 783 probe-sets used for molecular
subtyping of breast cancer and their gene cluster designations are
shown in Figure S3. Table S3 Thirty probe-sets representing cell-cycle
and proliferation genes Table S4 Probe-set IDs and genes from the
OncotypeDX and MammaPrint predictors. They were used to determine
recurrence risk scores. Table S5 Survival differences between patients
treated with CMF and CAF adjuvant chemotherapy in each molecular
subtype of breast cancer. Table S6 Statistical comparison of pertinent
clinical parameters between subtype I patients treated with CAF and
CMF adjuvant chemotherapy.
Additional file 2: Supplemental Methodology. Methodology includes
four sections: I) procedures for selection of classification probe-sets and
molecular subtyping by two steps k-means clustering analysis; II)
determination of cut-point values for estrogen receptor (ER),
progesterone receptor (PR) and HER2; III) scoring relative risk of distant
recurrence using genes of the OncotypeDX and MammaPrint predictor;
and IV) statistical comparison for concordance of differential gene
expression patterns among six breast cancer subtypes between KFSYSCC
dataset and public datasets from EMC (ref. [10]), Uppsala (ref. [19]), and
TRANSBIG (ref. [20]).
Additional file 3: Supplemental Figures S1-S7. This set of additional
files includes the following six supplemental figures. Figure S1 Cut-
points to determine positivity of ER, PR and HER2. Figure S2 Correlation
studies between immunohistochemistry and gene expression results for
ER, PR and HER2 statuses. Figure S3 Functional annotation of gene
clusters for breast cancer molecular subtyping. Figure S4 Dendrograms of
genes associated with cell cycle/proliferation, stromal reaction, wound
response and vascular endothelial normalization for characterizing breast
cancer molecular subtypes. Figure S5 Differential expression of the
selected genes by breast cancer molecular subtypes in different datasets.
Figure S6 Comparison of metastasis-free survival between Subtypes V
and VI breast cancer patients classified as Perou-Sørlie luminal A intrinsic
type in patients of the present study. Figure S7 Differential expression of
genes associated with epithelial-mesenchymal transition among breast
cancer molecular subtypes of the present study.
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